...
首页> 外文期刊>Clinical Biochemistry >Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient.
【24h】

Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient.

机译:质谱尿谱的树分析可将膀胱移行细胞癌与非癌性患者区分开。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Recent advances in proteomic profiling technologies, such as surface-enhanced laser desorption/ionization mass spectrometry (SELDI), have allowed preliminary profiling and identification of tumor markers in biological fluids in several cancer types and establishment of clinically useful diagnostic computational models. We developed a bioinformatics tool and used it to identify proteomic patterns in urine that distinguish transitional cell carcinoma (TCC) from noncancer. Methods: Proteomic spectra were generated by mass spectroscopy (surface-enhanced laser desorption and ionization). A preliminary "training" set of spectra derived from analysis of urine from 46 TCC patients, 32 patients with benign urogenital diseases (BUD), and 40 age-matched unaffected healthy men were used to train and develop a decision tree classification algorithm that identified a fine-protein mass pattern that discriminated cancer from noncancer effectively. A blinded test set, including 38 new cases, was used to determine the sensitivity and specificity of the classification system. Results: The algorithm identified a cluster pattern that, in the training set, segregated cancer from noncancer with sensitivity of 84.8% and specificity of 91.7%. The discriminatory pattern correctly identified. A sensitivity of 93.3% and a specificity of 87.0% for the blinded test were obtained when comparing the TCC vs. noncancer. Conclusions: These findings justify a prospective population-based assessment of proteomic pattern technology as a screening tool for bladder cancer in high-risk and general populations.
机译:背景:蛋白质组谱分析技术的最新进展,例如表面增强激光解吸/电离质谱(SELDI),已允许对几种癌症类型的生物体液中的肿瘤标志物进行初步谱分析和鉴定,并建立了临床上有用的诊断计算模型。我们开发了一种生物信息学工具,并将其用于识别尿液中的蛋白质组学模式,以区分非癌性移行细胞癌(TCC)。方法:通过质谱(表面增强的激光解吸和电离)生成蛋白质组谱。从46位TCC患者,32位良性泌尿生殖系统疾病(BUD)患者和40位年龄匹配的未受影响的健康男性的尿液分析中得出的初步“训练”光谱集用于训练和开发决策树分类算法,该算法可确定细蛋白质质量模式可有效区分癌症和非癌症。使用盲法测试集(包括38个新病例)来确定分类系统的敏感性和特异性。结果:该算法确定了一种训练模式下的聚类模式,该模式将癌症与非癌症分开,敏感性为84.8%,特异性为91.7%。正确识别出歧视模式。当比较TCC与非癌时,盲法的敏感性为93.3%,特异性为87.0%。结论:这些发现证明了对蛋白质组学技术进行基于人群的前瞻性评估是对高危人群和普通人群进行膀胱癌筛查的一种工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号